A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 17 Feb 2023
At a glance
- Drugs ASKB 589 (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Aosaikang Pharmaceutical
- 15 Feb 2023 Planned End Date changed from 1 Nov 2023 to 31 Dec 2025.
- 15 Feb 2023 Planned primary completion date changed from 1 Sep 2023 to 31 Dec 2024.
- 15 Feb 2023 Status changed from active, no longer recruiting to recruiting.